Amgen Saves Patent For Making Parathyroid Drug
European officials have dismissed an appeal seeking to defeat Amgen's patent for making a peptide that treats hyperparathyroidism resulting from kidney disease, saying the patent can stand because skilled inventors at...To view the full article, register now.
Already a subscriber? Click here to view full article